CYCC

Bio Green Med Solution, Inc. (CYCC) | Rumor.io

Bio Green Med Solution

CYCC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,581

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization2.1M

Earnings per share7.1K

Dividend yield (TTM)—

Revenue (annual)43K

Net income (annual)-11.2M

Social

What share of all stock conversation is about CYCC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% new	0% 0

Aug 27

Cyclacel Pharmaceuticals, Inc. ($CYCC) is involved in research and development of cancer therapies.
The company's work focuses on the development of small molecule therapeutics and other innovative treatments.
$CYCC's research efforts are aimed at addressing various types of cancer, including cancer-related diseases.

Generated by AI

Sentiment

Of the messages about CYCC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.39% +16.17
Bearish	—	—	—	1.61% -16.17

Bullish· Aug 5

Cyclacel Pharmaceuticals' $CYCC is expected to launch its FDA-approved Leukemia drug PHYRAGO in Sep. 2025, with a potential price target of $20+.
The company has a relatively low float of 0.62M shares, which may contribute to its high volatility and potential for aggressive price movements.
$CYCC has delivered solid gains, with a recent pre-market surge of +38.63% and an after-hours increase of 34.56%, driven by positive preclinical results and the announcement of a new deal with Handa.

Bearish· Jul 19

$CYCC's recent equity offering has led to a 36% drop in shares premarket, with some investors criticizing the company's dilution of shareholder value.
The company's planned public offering of units has caused a 27% slump in shares premarket, with robust volume indicating significant investor concern.
$CYCC's decision to issue 300% new shares, including $2 warrants, has been criticized as a major dilution of shareholder value, with some investors comparing it to other companies that have engaged in similar practices.

Generated by AI

Topics

Of the messages about CYCC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	80%
Controversies	—	—	—	6.67%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.33%

Earnings· Aug 9

Cyclacel Pharmaceuticals, Inc. (CYCC) is hosting its Q2 earnings call today at 4:30pm Eastern.
The call will be streamed live and available for replay.
CYCC investors can tune in to the call for updates on the company's financial performance.

Announcements· Aug 5

Cyclacel Pharmaceuticals highlighted preclinical data showing that cancer of the biliary tract is sensitive to plogosertib.
The company enacted a 1:15 reverse stock split on July 7 and has a new outstanding share count of approximately 1.5 million.
Cyclacel Pharmaceuticals entered an exclusive U.S. deal with Handa to launch FDA-approved Leukemia drug PHYRAGO in September 2025.

Technical Analysis· Apr 30

$CYCC is near its demand zone, potentially reversing its trend.
The stock is holding a back-test level at $2.00 and has reached $2.70, with potential next zones to clear at $2.80-3.00.
A bullish reversal divergence has been identified on the daily chart of Cyclacel Pharmaceuticals Inc. ($CYCC), with a 50% increase in the stock's value.

Generated by AI

Community

Of the messages about CYCC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	46.39%
Newcomers	100%	100%	100%	53.61%

Regulars· Aug 7

$CYCC regulars are noting a strong move in the stock, which could be driven by the company's progress in its clinical trials and pipeline development.
There is speculation among regulars about the potential for a partnership or acquisition that could further enhance the company's prospects.
Some regulars are expressing optimism about the company's prospects in the biotech space, citing the potential for Cyclacel's treatments to address significant unmet medical needs.

Newcomers· Aug 5

Newcomers to $CYCC are excited about the stock's 35% run after Cyclacel Pharmaceuticals presented promising preclinical data on plogosertib for biliary tract cancer.
The company's stock is being analyzed for its potential to break out above $15.00, with a possible target at $15.20 and a 5-minute support level at $12.60.
Cyclacel Pharmaceuticals has filed a 424B3 form with the SEC, detailing a plan to offer up to 2,821,151 shares of its common stock, including shares of its Class F common stock and warrants.

Generated by AI

News

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a...

1mo agoBarchart.com

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

1mo agoBarchart.com

Also Discussed

Investors talking about CYCC also mention

#	Name	Attention
1	Benitec Biopharma LtdBNTC	0%new
2	Crescent Biopharma Inc.CBIO	0%new
3	BIOC - Biocept, Inc.	——
4	DRRX - DURECT Corporation	——
5	QIPT - Quipt Home Medical Corp.	——
6	Pulmatrix Inc.PULM	0%0
7	XOMA CorporationXOMA	0%0
8	Oncolytics Biotech Inc.ONCY	0%0
9	AKLI - Akili, Inc.	——
10	Moleculin Biotech, Inc.MBRX	0%0

Bio Green Med Solution, Inc.

Healthcare
Biotechnology

Bio Green Med Solution, Inc. is a diversified biopharmaceutical and fire protection company focused on developing innovative cancer medicines and providing fire safety solutions. Emerging from its former identity as Cyclacel Pharmaceuticals, the company leverages expertise in cell cycle, transcriptional regulation, and mitosis control biology to develop targeted cancer therapies, including novel Polo-like kinase 1 (PLK1) inhibitors such as plogosertib. In addition to its pharmaceutical research, Bio Green Med Solution offers a wide array of protective and fire safety equipment, encompassing fire extinguishers, foam systems, and fire-resistant materials for domestic and international markets. Headquartered in Malaysia, it integrates scientific innovation with practical safety solutions, maintaining a disciplined diversification strategy aimed at sustainable growth. The company's leadership and board possess extensive public company management experience across various sectors, underpinning its commitment to long-term value creation for stakeholders. Its dual focus on cutting-edge biotechnology and fire safety positions it uniquely within healthcare and industrial markets.

Website

Location

Level 10

Kuala Lumpur, NJ, 592000

Malaysia

Social

What share of all stock conversation is about CYCC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% new	0% 0

Aug 27

Cyclacel Pharmaceuticals, Inc. ($CYCC) is involved in research and development of cancer therapies.
The company's work focuses on the development of small molecule therapeutics and other innovative treatments.
$CYCC's research efforts are aimed at addressing various types of cancer, including cancer-related diseases.

Generated by AI

Sentiment

Of the messages about CYCC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.39% +16.17
Bearish	—	—	—	1.61% -16.17

Bullish· Aug 5

Cyclacel Pharmaceuticals' $CYCC is expected to launch its FDA-approved Leukemia drug PHYRAGO in Sep. 2025, with a potential price target of $20+.
The company has a relatively low float of 0.62M shares, which may contribute to its high volatility and potential for aggressive price movements.
$CYCC has delivered solid gains, with a recent pre-market surge of +38.63% and an after-hours increase of 34.56%, driven by positive preclinical results and the announcement of a new deal with Handa.

Bearish· Jul 19

$CYCC's recent equity offering has led to a 36% drop in shares premarket, with some investors criticizing the company's dilution of shareholder value.
The company's planned public offering of units has caused a 27% slump in shares premarket, with robust volume indicating significant investor concern.
$CYCC's decision to issue 300% new shares, including $2 warrants, has been criticized as a major dilution of shareholder value, with some investors comparing it to other companies that have engaged in similar practices.

Generated by AI

Topics

Of the messages about CYCC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	80%
Controversies	—	—	—	6.67%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.33%

Earnings· Aug 9

Cyclacel Pharmaceuticals, Inc. (CYCC) is hosting its Q2 earnings call today at 4:30pm Eastern.
The call will be streamed live and available for replay.
CYCC investors can tune in to the call for updates on the company's financial performance.

Announcements· Aug 5

Cyclacel Pharmaceuticals highlighted preclinical data showing that cancer of the biliary tract is sensitive to plogosertib.
The company enacted a 1:15 reverse stock split on July 7 and has a new outstanding share count of approximately 1.5 million.
Cyclacel Pharmaceuticals entered an exclusive U.S. deal with Handa to launch FDA-approved Leukemia drug PHYRAGO in September 2025.

Technical Analysis· Apr 30

$CYCC is near its demand zone, potentially reversing its trend.
The stock is holding a back-test level at $2.00 and has reached $2.70, with potential next zones to clear at $2.80-3.00.
A bullish reversal divergence has been identified on the daily chart of Cyclacel Pharmaceuticals Inc. ($CYCC), with a 50% increase in the stock's value.

Generated by AI

Community

Of the messages about CYCC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	46.39%
Newcomers	100%	100%	100%	53.61%

Regulars· Aug 7

$CYCC regulars are noting a strong move in the stock, which could be driven by the company's progress in its clinical trials and pipeline development.
There is speculation among regulars about the potential for a partnership or acquisition that could further enhance the company's prospects.
Some regulars are expressing optimism about the company's prospects in the biotech space, citing the potential for Cyclacel's treatments to address significant unmet medical needs.

Newcomers· Aug 5

Newcomers to $CYCC are excited about the stock's 35% run after Cyclacel Pharmaceuticals presented promising preclinical data on plogosertib for biliary tract cancer.
The company's stock is being analyzed for its potential to break out above $15.00, with a possible target at $15.20 and a 5-minute support level at $12.60.
Cyclacel Pharmaceuticals has filed a 424B3 form with the SEC, detailing a plan to offer up to 2,821,151 shares of its common stock, including shares of its Class F common stock and warrants.

Generated by AI

Bio Green Med Solution

Social

Aug 27

Bullish· Aug 5

Bearish· Jul 19

Earnings· Aug 9

Announcements· Aug 5

Technical Analysis· Apr 30

Regulars· Aug 7

Newcomers· Aug 5

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Also Discussed

Bio Green Med Solution, Inc.

Company Information

Location

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Also Discussed

Social

Aug 27

Bullish· Aug 5

Bearish· Jul 19

Earnings· Aug 9

Announcements· Aug 5

Technical Analysis· Apr 30

Regulars· Aug 7

Newcomers· Aug 5